ArticleInfectious diseases & clinical microbiology2025
Surge of Chikungunya Cases in Central India, Post-COVID-19 Pandemic.
Article in Infectious diseases & clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genomic and Immunological Insights Into Chikungunya Virus Evolution During the 2018 and 2023-24 Outbreaks in Southern India.Journal of medical virology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Chikungunya virus (CHIKV) the causative agent of chikungunya fever, has caused several outbreaks in India since its emergence in 2006. However, studies in central India remain limited. In 2024, following the COVID-19 pandemic, a surge in chikungunya cases was reported in the state of Madhya Pradesh, located in central India. This study aimed to evaluate the incidence of chikungunya cases in this region. Materials and Methods: This prospective study was conducted in Madhya Pradesh between July 2024 and February 2025. Chikungunya virus infection was confirmed using reverse transcriptase real-time polymerase chain reaction (RT-PCR) to detect viral RNA during the acute phase and in cases of viral co-infection. Patients with an acute onset of high-grade fever (≤7 days from symptom onset) and severe arthralgia or arthritis, with or without a skin rash, were considered to have suspected CHIKV infection according to the case definition by the Government of India. Because of overlapping clinical presentations, patients were also tested for dengue virus (DENV) infection. Demographic and clinical data of CHIKV-positive patients were analyzed. Co-infected samples were further analyzed for viral load using Truenat® Dengue/Chikungunya chip-based real-time duplex PCR test (Molbio Diagnostics Pvt. Ltd., Goa, India). Positive patients were followed for an additional two months. Results: Of 1878 samples tested, 1105 (58.9%) were positive for CHIKV. The positivity rate was 60.2% ± 0.009 (mean ± standard deviation [SD]) among males and 57.5% ± 0.07 among females. The number of cases in 2024 was significantly higher than in previous years ( Conclusion: The true incidence of chikungunya in Madhya Pradesh remains underestimated and underreported. Timely real-time PCR-based diagnosis of CHIKV infection is crucial for an accurate assessment of the disease burden and targeted public health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.